Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 33.3%High 4 · 66.7%

Overall survival · women with advanced breast cancer without bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.09]
3 studies · 330 participants
High

Overall survival · women with metastatic breast cancer with bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 1.01 [0.91, 1.11]
7 studies · 1935 participants
Moderate

Overall survival · women with early breast cancer

Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.91 [0.83, 0.99]
9 studies · 13949 participants
High

Overall survival postmenopausal women · women with early breast cancer

Bisphosphonates leads to lower overall survival postmenopausal women compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 0.77 [0.66, 0.9]
4 studies · 6048 participants
High

Overall survival: pre‐ or perimenopausal women · women with early breast cancer

Bisphosphonates showed no clear difference in overall survival: pre‐ or perimenopausal women compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
HR 1.03 [0.86, 1.22]
2 studies · 3501 participants
High

Overall survival## · patients with multiple myeloma

The intervention showed no clear difference in overall survival## (moderate certainty).

1 finding from 1 review

Bisphosphonates in multiple myeloma: an updated network meta‐analysis 2017 · Cochrane Headline outcomes only
HR 0.9 [0.76, 1.07]
14 studies · 2706 participants
Moderate